Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:public_company |
| gptkbp:CEO |
Scott Koenig
|
| gptkbp:collaboratedWith |
gptkb:Incyte
gptkb:Janssen_Biotech gptkb:Zai_Lab |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
immuno-oncology
monoclonal antibody therapeutics |
| gptkbp:foundedIn |
2000
|
| gptkbp:founder |
Scott Koenig
|
| gptkbp:headquartersLocation |
gptkb:Rockville,_Maryland,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
MacroGenics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableEvent |
FDA approval of Margetuximab in 2020
|
| gptkbp:numberOfEmployees |
approximately 300
|
| gptkbp:product |
Enoblituzumab
Flotetuzumab Margetuximab Retifanlimab |
| gptkbp:stockSymbol |
MGNX
|
| gptkbp:tradedOn |
NASDAQ: MGNX
|
| gptkbp:website |
https://www.macrogenics.com/
|
| gptkbp:bfsParent |
gptkb:WuXi_Biologics
|
| gptkbp:bfsLayer |
7
|